Log in to your account:
Pfizer (PFE) Risk/Reward Seems Favorable, But Not Enough for Upgrade - BMO
January 31, 2019 12:21 PM
BMO Capital analyst Alex Arfaei said Pfizer's (NYSE: PFE) risk/reward in PFE remains favorable, but given the stock's strong performance ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients
February 1, 2019 9:21 AM